Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May advance oral GPIIb/IIIa antagonist development; leaves open clinical efficacy and safety.
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTOrally Active Non-Peptide Fibrinogen Receptor (GpIIb/IIIa) Antagonists: Identification of 4-[4-[4-(Aminoimino methyl)phenyl]-1-piperazinyl]-1- piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic AgentColin D. Eldred, Brian Evans, Sean Hindley, Brian D. Judkins, Henry A. Kelly, John Kitchin, Philip Lumley, Barry Porter, Barry C. Ross, and Cite this: J. Med. Chem. 1994, 37, 23, 3882–3885Publication Date (Print):November 1, 1994Publication History Published online1 May 2002Published inissue 1 November 1994https://pubs.acs.org/doi/10.1021/jm00049a006https://doi.org/10.1021/jm00049a006research-articleACS PublicationsRequest reuse permissionsArticle Views307Altmetric-Citations41LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Eldred et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: